Browsing by Subject "Nitric Oxide"

Now showing 1 - 8 of 8
  • Thumbnail Image
    Item
  • Thumbnail Image
    Item
    A comparison of nasal nitric oxide measurement modes
    (Wiley, 2017-11) Deschamp, A.R.; Schornick, L.; Clem, C.; Hazucha, M.; Shapiro, A.J.; Davis, S.D.; Pediatrics, School of Medicine
  • Thumbnail Image
    Item
    Effect of Inhibition of S-Nitrosoglutathione Reductase on the NF-κB Pathway
    (2009-09-30T19:08:58Z) Fears, Sharry L.; Sanghani, Sonal P.; Sanghani, Paresh C.; Bosron, William F.
    S-nitrosoglutathione reductase (GSNOR) also known as glutathione- dependent formaldehyde dehydrogenase (FDH), is a zinc-dependent dehydrogenase. GSNOR oxidizes long chain alcohols to an aldehyde with the help of a molecule of NAD+. GSNOR was initially identified as FDH because of its role in the formaldehyde detoxification pathway. The only S-nitrosothiol (SNO) substrate recognized by GSNOR is GSNO. A transnitrosation reaction transfers NO from nitrosylated proteins or S-nitrosothiols (RSNO) to glutathione to form S-nitrosoglutathione. This GSNO is finally converted to glutathione disulfide (GSSG) by a two step mechanism. Cellular GSNO is a nitric oxide reservoir that can either transfer to or remove from the proteins a NO group. Reduction of GSNO by GSNOR depletes this reservoir and therefore indirectly regulates protein nitrosylation. GSNOR inhibitors which can increase the basal GSNO levels will be another potential therapy. Several GSNOR inhibitors were identified in our laboratory and the aim of this study was to understand their cellular effects. One of the experiments studied the effect of the compound on protein-SNO. The role of nitric oxide in regulation of NF-κB pathway is reviewed by Bove and van der Vliet. We focused on identification of nitrosylated proteins using protein specific antibodies. We identified nitrosylation of IKKβ. So the question raised was whether nitrosylation of IKKβ affects its activity. IKKβ is responsible for phosphorylation of IκBα and phosphorylation of IκBα results in its degradation and activation of NF-κB pathway. Therefore, we studied the phosphorylation of IκBα in the presence of inhibitor C3. Results showed a dose-dependent decrease of pIκB. So the next question was whether the phosphorylation of IKKβ was affected by nitrosylation. We did not detect any change in pIKKβ with different concentrations of C3. The decreased degradation of IκBα caused by C3 translated into decreased NF-κB activity as seen by a dose-dependent decrease in amounts of ICAM-1 with increasing C3 concentration. This data supports the premise that the activity of transcription factor NF-κB is suppressed by inhibiting GSNOR with compound C3
  • Thumbnail Image
    Item
    Exhaled nitric oxide during infancy as a risk factor for asthma and airway hyperreactivity
    (European Respiratory Society, 2015-01) Chang, Daniel; Yao, Weiguo; Tiller, Christina J.; Kisling, Jeffrey; Slaven, James E.; Yu, Zhangsheng; Kaplan, Mark H.; Tepper, Robert S.; Department of Pediatrics, IU School of Medicine
    Childhood asthma is often characterised by elevated exhaled nitric oxide (eNO), decreased lung function, increased airway reactivity and atopy; however, our understanding of when these phenotypic airway characteristics develop remains unclear. This study evaluated whether eNO, lung function, airway reactivity and immune characteristics during infancy are risk factors of asthma at age 5 years. Infants with eczema, enrolled prior to wheezy illness (n=116), had eNO, spirometry, airway reactivity and allergen sensitisation assessed at entry to the study and repeated at age 5 years (n=90). Increasing eNO at entry was associated with an increased risk of asthma (p=0.037) and increasing airway reactivity (p=0.015) at age 5 years. Children with asthma at 5 years of age had a greater increase in eNO between infancy and age 5 years compared with those without asthma (p=0.002). Egg sensitisation at entry was also associated with an increased risk of asthma (p=0.020), increasing eNO (p = 0.002) and lower forced expiratory flows (p=0.029) as a 5 year-old. Our findings suggest that, among infants at high risk for developing asthma, eNO early in life may provide important insights into the subsequent risk of asthma and its airway characteristics.
  • Thumbnail Image
    Item
    Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-γ in a nitric oxide-dependent manner
    (The American Association of Immunologists, 2010-10-01) Fernandez-Boyanapalli, Ruby; McPhillips, Kathleen A.; Frasch, S. Courtney; Janssen, Wiliam J.; Dinauer, Mary C.; Riches, David W.H.; Henson, Peter M.; Byrne, Aideen; Bratton, Donna L.; Department of Medicine, IU School of Medicine
    Immunodeficiency in chronic granulomatous disease (CGD) is well characterized. Less understood are exaggerated sterile inflammation and autoimmunity associated with CGD. Impaired recognition and clearance of apoptotic cells resulting in their disintegration may contribute to CGD inflammation. We hypothesized that priming of macrophages (Ms) with IFN-γ would enhance impaired engulfment of apoptotic cells in CGD. Diverse M populations from CGD (gp91(phox)(-/-)) and wild-type mice, as well as human Ms differentiated from monocytes and promyelocytic leukemia PLB-985 cells (with and without mutation of the gp91(phox)), demonstrated enhanced engulfment of apoptotic cells in response to IFN-γ priming. Priming with IFN-γ was also associated with increased uptake of Ig-opsonized targets, latex beads, and fluid phase markers, and it was accompanied by activation of the Rho GTPase Rac. Enhanced Rac activation and phagocytosis following IFN-γ priming were dependent on NO production via inducible NO synthase and activation of protein kinase G. Notably, endogenous production of TNF-α in response to IFN-γ priming was critically required for inducible NO synthase upregulation, NO production, Rac activation, and enhanced phagocytosis. Treatment of CGD mice with IFN-γ also enhanced uptake of apoptotic cells by M in vivo via the signaling pathway. Importantly, during acute sterile peritonitis, IFN-γ treatment reduced excess accumulation of apoptotic neutrophils and enhanced phagocytosis by CGD Ms. These data support the hypothesis that in addition to correcting immunodeficiency in CGD, IFN-γ priming of Ms restores clearance of apoptotic cells and may thereby contribute to resolution of exaggerated CGD inflammation.
  • Thumbnail Image
    Item
    Nitric oxide stress and activation of AMP-activated protein kinase impair β-cell sarcoendoplasmic reticulum calcium ATPase 2b activity and protein stability
    (Nature Publishing Group, 2015-06-18) Tong, X.; Kono, T.; Evans-Molina, C.; Department of Medicine, IU School of Medicine
    The sarcoendoplasmic reticulum Ca(2+) ATPase 2b (SERCA2b) pump maintains a steep Ca(2+) concentration gradient between the cytosol and ER lumen in the pancreatic β-cell, and the integrity of this gradient has a central role in regulated insulin production and secretion, maintenance of ER function and β-cell survival. We have previously demonstrated loss of β-cell SERCA2b expression under diabetic conditions. To define the mechanisms underlying this, INS-1 cells and rat islets were treated with the proinflammatory cytokine interleukin-1β (IL-1β) combined with or without cycloheximide or actinomycin D. IL-1β treatment led to increased inducible nitric oxide synthase (iNOS) gene and protein expression, which occurred concurrently with the activation of AMP-activated protein kinase (AMPK). IL-1β led to decreased SERCA2b mRNA and protein expression, whereas time-course experiments revealed a reduction in protein half-life with no change in mRNA stability. Moreover, SERCA2b protein but not mRNA levels were rescued by treatment with the NOS inhibitor l-NMMA (NG-monomethyl L-arginine), whereas the NO donor SNAP (S-nitroso-N-acetyl-D,L-penicillamine) and the AMPK activator AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) recapitulated the effects of IL-1β on SERCA2b protein stability. Similarly, IL-1β-induced reductions in SERCA2b expression were rescued by pharmacological inhibition of AMPK with compound C or by transduction of a dominant-negative form of AMPK, whereas β-cell death was prevented in parallel. Finally, to determine a functional relationship between NO and AMPK signaling and SERCA2b activity, fura-2/AM (fura-2-acetoxymethylester) Ca(2+) imaging experiments were performed in INS-1 cells. Consistent with observed changes in SERCA2b expression, IL-1β, SNAP and AICAR increased cytosolic Ca(2+) and decreased ER Ca(2+) levels, suggesting congruent modulation of SERCA activity under these conditions. In aggregate, these results show that SERCA2b protein stability is decreased under inflammatory conditions through NO- and AMPK-dependent pathways and provide novel insight into pathways leading to altered β-cell calcium homeostasis and reduced β-cell survival in diabetes.
  • Thumbnail Image
    Item
  • Thumbnail Image
    Item
    Role of Postsynaptic Density Protein 95 (PSD95) and Neuronal Nitric Oxide Synthase (NNOS) Interaction in the Regulation of Conditioned Fear
    (2019-10) Li, Liangping; Johnson, Philip L.; Lahiri, Debomoy K.; Shekhar, Anantha; Truitt, William A.; Xu, Xiao-Ming
    Stimulation of N-­methyl-­D-­aspartic acid receptors (NMDARs) and the resulting activation of neuronal nitric oxide synthase (nNOS) are critical for fear memory formation. A variety of previously studied NMDAR antagonists and NOS inhibitors can disrupt fear memory, but they also affect many other CNS functions. Following NMDAR stimulation, efficient activation of nNOS requires linking nNOS to a scaffolding protein, the postsynaptic density protein 95 (PSD95). We hypothesized that PSD95-­nNOS interaction in critical limbic regions (such as amygdala and hippocampus) during fear conditioning is important in regulating fear memory formation, and disruption of this protein-­protein binding may cause impairments in conditioned fear memory. Utilizing co-­immunoprecipitation, electrophysiology and behavioral paradigms, we first showed that fear conditioning results in significant increases in PSD95-­nNOS binding within the basolateral amygdala (BLA) and the ventral hippocampus (vHP) in a time-­dependent manner, but not in the medial prefrontal cortex (mPFC). Secondly, by using ZL006, a small molecule disruptor of PSD95-­ nNOS interaction, it was found that systemic and intra-­BLA disruption of PSD95-­ nNOS interaction by ZL006 impaired the consolidation of cue-­induced fear. In contrast, disruption of PSD95-­nNOS interaction within the vHP did not affect the consolidation of cue-­induced fear, but significantly impaired the consolidation of context-­induced fear. At the cellular level, disruption of PSD95-­nNOS interaction with ZL006 was found to impair long-­term potentiation (LTP) in the BLA neurons. Finally, unlike NMDAR antagonist MK-­801, ZL006 is devoid of adverse effects on many other CNS functions, such as motor function, social activity, cognitive functions in tasks of object recognition memory and spatial memory. These findings collectively demonstrated that PSD95-­nNOS interaction within the conditioned fear network appears to be a key molecular step in regulating synaptic plasticity and the consolidation of conditioned fear. Disruption of PSD95-­nNOS interaction holds promise as a novel treatment strategy for fear-­ motivated disorders, such as post-­traumatic stress disorder and phobias.